Eagle Health Investments Lp: Significant Stock Purchases & Sales in Q2 2026
A detailed analysis of Eagle Health Investments' portfolio changes during the second quarter of 2026, highlighting major buying and selling activities.
Portfolio Overview
Eagle Health Investments Lp managed a substantial portfolio valued at $565.6 million as of June 30th, 2026. The investment strategy appears heavily concentrated in the Healthcare sector.
Major Purchases This Quarter
This quarter saw notable buying activity by Eagle Health Investments Lp, most significantly increasing its stake in INSMED INC (INSM). The fund acquired a substantial 71.28% more shares of this company known for developing treatments for rare diseases.
Alongside the significant increase in INSM, Eagle Health Investments also initiated new positions or significantly boosted existing ones with several other companies:
- INSMED INC (INSM): Acquired 159,859 additional shares.
- AXSOME THERAPEUTICS INC. (AXSM): Entered a new position with a 100% increase in shares acquired during this period.
- IONIS PHARMACEUTICALS INC (IONS): Entered a new position or significantly increased holdings by acquiring all shares during the quarter, representing a 100% increase from prior.
- DIANTHUS THERAPEUTICS INC (DNTH): Acquired all shares during this period, showing a significant 100% increase in holdings.
- AVALO THERAPEUTICS INC (AVTX): Entered a new position or significantly increased holdings by acquiring all shares during the quarter, representing a 100% increase from prior.
Significant Sales and Decreases
Eagle Health Investments Lp also reduced its exposure in certain Healthcare companies this quarter:
- NATERA INC (NTRA): Sold shares resulting in an 87.0% decrease from prior period holdings.
- GUARDANT HEALTH INC (GH): Reduced its position by 3.09%, indicating a modest divestment activity.
Other Portfolio Changes and Insights
The fund experienced significant share changes in other stocks, though the percentage shifts were less dramatic than new purchases or major sales:
- BIOMARIN PHARMACEUTICAL INC (BMRN): Increased its stake by 23.5%.
- SCHOLAR ROCK HLDG CORP (SRRK): Added shares, increasing the position by 12.4%.
- PROTAGONIST THERAPEUTICS INC (PTGX): Increased its stake by 38.47%.
Conclusion: Focus on Healthcare Innovation
The overall portfolio allocation remains heavily weighted towards the Healthcare sector, which represents approximately 87.78% of the total value ($506 million). Eagle Health Investments Lp appears to favor companies involved in developing treatments for rare diseases and other therapeutic areas within biopharma.